1C84 Herman, Jay H. - Thomas Jefferson University - Thomas Jefferson University

Jay H. Herman, MD

Contact Dr. Herman

111 South 11th Street
Gibbon Building, Room 8220
Philadelphia, PA 19107

(215) 955-8244
(215) 923-9387 fax

Most Recent Peer-reviewed Publications

  1. Cost of Purchased Versus Produced Plasma from Donor Recruitment Through Transfusion
  2. Does therapeutic plasma exchange have a role in the treatment of prosthetic hip–associated cobalt toxicity? A case report and literature review
  3. Red blood cell transfusion increases the risk of thrombotic events in patients with subarachnoid hemorrhage
  4. Sensitization, pathologic, and imaging findings comparing symptomatic and quiescent failed renal allografts
  5. RhIG for the treatment of immune thrombocytopenia: Consensus and controversy (CME)
  6. In Reply
  7. Prevention of D sensitization after mismatched transfusion of blood components: Toward optimal use of RhIG
  8. Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity
  9. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation
  10. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation
  11. Acute hypertensive transfusion reactions
  12. Alternative explanation for "muddy plasma" [3]
  13. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature
  14. Apheresis platelet transfusions: Does ABO matter?
  15. Platelet dosing
  16. Single-donor platelets reduce the risk of septic platelet transfusion reactions.
  17. Severe cutaneous ulceration following treatment with thalidomide for GVHD
  18. Early prediction of poor hematopoietic progenitor cell (HPC) mobilization
  19. Economic consequences of alterations in platelet transfusion dose: Analysis of a prospective, randomized, double-blind trial
  20. Considerations in the selection of a platelet component: Apheresis versus whole blood-derived